Compare NSYS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | PULM |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 18.3M |
| IPO Year | N/A | N/A |
| Metric | NSYS | PULM |
|---|---|---|
| Price | $6.94 | $4.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.8K | 5.4K |
| Earning Date | 11-13-2025 | 10-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,672,000.00 | $3,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.50 | $3.90 |
| 52 Week High | $12.40 | $10.40 |
| Indicator | NSYS | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 33.89 |
| Support Level | $6.76 | $4.32 |
| Resistance Level | $7.05 | $4.67 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 28.96 | 16.66 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).